- References (2)
Product nameSrc Kinase Inhibitor I (SKI-1)
DescriptionPotent, selective and dual site Src tyrosine kinase family inhibitor
Biological descriptionPotent, selective and dual site Src family tyrosine kinase inhibitor (IC50 values are 44 and 88 nM for Src and Lck, respectively). Cell-permeable, reversible and ATP-competitive. Interacts with both ATP and peptide-binding sites. Additionally inhibits VEGFR2 and C-fms (IC50 values are 0.32 and 30 µM, respectively). Induces apoptosis.
Storage instructionsStore at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 50 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120839 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
ab11512 staining E cadherin in SW480 cells treated with Src Kinase Inhibitor I (SKI-1) (ab120839), by ICC/IF. Increase of E cadherin expression correlates with increased concentration of Src Kinase Inhibitor I (SKI-1), as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120839 (Src Kinase Inhibitor I (SKI-1)) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab11512 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rat polyclonal antibody (ab98386) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This product has been referenced in:
- Leung EL et al. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res 8:578-91 (2010). Read more (PubMed: 20371672) »
- Leung EL et al. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res 7:923-32 (2009). Read more (PubMed: 19491201) »
- Bain J et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315 (2007). Read more (PubMed: 17850214) »
- Tian G et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry 40:7084-91 (2001). Read more (PubMed: 11401553) »